Biopharmaceutical company Ferring Pharmaceuticals on Wednesday announced a collaboration agreement with Igenomix to advance care in reproductive medicine and maternal health.
The two-year research collaboration will focus on the discovery of novel targets and disease mechanisms in infertility and pregnancy-related conditions, including preeclampsia, with the goal of developing innovative diagnostic and therapeutic strategies in these areas of high unmet need.
Under the agreement the partners plan to establish a research hub in Boston, bringing together scientists from both companies to investigate molecular signatures, develop novel functional genomic systems and create translational tools to study for embryo implantation, endometrial microbiome interaction and decidualization biology.
The collaboration combines Ferring's therapeutic expertise with Igenomix's diagnostic capabilities.
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
argenx advances ARGX-119 to registrational study for congenital myasthenic syndromes
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
Sanofi's riliprubart receives orphan drug designation in Japan for CIDP
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Hikma Pharmaceuticals USA announces USD1bn of new US investment
UCB reports positive Phase 3 results for fenfluramine in CDKL5 deficiency disorder